3SBIO(01530),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01530 3SBIO

Closed 04-10 16:09:20

22.960

+0.160

+0.70%

High23.160	Low22.380	Vol30.02M
Open23.160	D1 Closing22.800	Amplitude3.42%
Mkt Cap58.27B	Tradable Cap58.27B	Total Shares2.54B
T/O684.38M	T/O Rate1.18%	Tradable Shares2.54B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"3SBIO","latestPrice":22.96,"timestamp":1775808560004,"preClose":22.8,"halted":0,"volume":30015153,"delay":0,"changeRate":0.007017543859649129,"floatShares":2538000000,"shares":2538000000,"eps":3.93369032419773,"marketStatus":"Closed","change":0.16,"latestTime":"04-10 16:09:20","open":23.16,"high":23.16,"low":22.38,"amount":684378101,"amplitude":0.034211,"askPrice":22.96,"askSize":278000,"bidPrice":22.92,"bidSize":14000,"shortable":3,"etf":0,"ttmEps":3.93369032419773,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":5,"adr":0,"listingDate":1433952000000,"exchange":"SEHK","adjPreClose":22.8,"dividendRate":0.011066,"openAndCloseTimeList":[[1775784600000,1775793600000],[1775797200000,1775808000000]],"volumeRatio":0.505821,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01530","defaultTab":"news","newsList":[{"id":"1166924251","title":"Can Southbound Capital Propel 3SBIO's Stock Rebound Post-Earnings?","url":"https://stock-news.laohu8.com/highlight/detail?id=1166924251","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166924251?lang=en_us&edition=full_marsco","pubTime":"2026-04-10 16:03","pubTimestamp":1775808231,"startTime":"0","endTime":"0","summary":"On May 20 last year, 3SBIO (01530) entered into a major business development (BD) transaction with Pfizer, with a total potential value exceeding $6 billion. The deal set a new record for upfront...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","BK1583","BK1593","BK1161","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198055679","title":"3SBio Sets 23 April 2026 Vote on In-Specie Dividend of Mandi Shares as Part of Planned Spin-Off","url":"https://stock-news.laohu8.com/highlight/detail?id=1198055679","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198055679?lang=en_us&edition=full_marsco","pubTime":"2026-04-01 16:49","pubTimestamp":1775033354,"startTime":"0","endTime":"0","summary":"3SBio Inc. has issued a circular proposing a conditional special dividend to be executed through an in-specie distribution of all Mandi Inc. shares currently held by the group. The move is tied to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111420823","title":"3SBio Convenes 23 April 2026 EGM to Ratify In-Specie Special Dividend of Full Mandi Inc. Shareholding","url":"https://stock-news.laohu8.com/highlight/detail?id=1111420823","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111420823?lang=en_us&edition=full_marsco","pubTime":"2026-04-01 16:48","pubTimestamp":1775033320,"startTime":"0","endTime":"0","summary":"3SBio Inc. has scheduled an Extraordinary General Meeting (EGM) for 23 April 2026 at 10:00 a.m., to be held at the company’s headquarters in Shenyang, People’s Republic of China. The sole ordinary...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624956445","title":"3SBio announces extraordinary general meeting to approve Mandi shares distribution dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2624956445","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624956445?lang=en_us&edition=full_marsco","pubTime":"2026-04-01 16:32","pubTimestamp":1775032372,"startTime":"0","endTime":"0","summary":"3SBio set an extraordinary general meeting in Shenyang, China on April 23, 2026.Shareholders will vote on declaring a conditional special dividend funded from share premium via an in-specie distribution of all Mandi shares held by 3SBio to qualifying shareholders.Resolution also seeks authorization for board to implement distribution, including setting record date, distribution basis, and mechanics for transferring Mandi shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 3SBio Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL1LCCl1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","01530","BK1161","BK1583","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147015943","title":"Stock Track | 3SBIO Soars 11.66% Intraday as CICC Maintains Outperform Rating with 61% Upside Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1147015943","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147015943?lang=en_us&edition=full_marsco","pubTime":"2026-04-01 14:29","pubTimestamp":1775024973,"startTime":"0","endTime":"0","summary":"3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.CICC maintained its Outperform rating on 3SBIO with a target price of...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101073740","title":"CICC Maintains Outperform Rating on 3SBIO with HK$36.5 Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1101073740","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101073740?lang=en_us&edition=full_marsco","pubTime":"2026-04-01 13:50","pubTimestamp":1775022646,"startTime":"0","endTime":"0","summary":"CICC has released a research report stating that, considering the timing of profit recognition from out-licensing revenue, it has lowered its net profit forecast for 3SBIO (01530) for 2026 by 47% to...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","01530","EWH","HK0000165453.HKD","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623973589","title":"3SBio - 2025 Adj Net Profit Attributable to Shareholders RMB 8.45 Bln, up 264.6% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2623973589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623973589?lang=en_us&edition=full_marsco","pubTime":"2026-03-31 20:13","pubTimestamp":1774959180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA38Q7SG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","HK0000165453.HKD","BK1161","BK1593","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623589921","title":"3SBio - Declares 2025 Final Dividend of HKD 0.25 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2623589921","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623589921?lang=en_us&edition=full_marsco","pubTime":"2026-03-31 20:13","pubTimestamp":1774959180,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA38Q7SG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000165453.HKD","BK1593","BK1161","BK1583","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623589931","title":"3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2623589931","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623589931?lang=en_us&edition=full_marsco","pubTime":"2026-03-31 20:13","pubTimestamp":1774959180,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc.  today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs in innovative R&D and strategic global collaboration, the company delivered a high-quality performance with both quantitative and qualitative growth: annual revenue hit RMB 17.7 billion, a historic breakthrough past the RMB 10 billion mark, representing a 94.3% year-on-year  increase; net profit attributable to shareholders of the parent company reached RMB 8.48 billion, surging 305.8% YoY; adjusted net profit attributable to shareholders of the parent company stood at RMB 8.45 billion, a 264.6% YoY rise. The company's profitability achieved a leap-forward growth, demonstrating robust growth momentum.Under the collaboration agreement, 3SBio granted Pfizer exclusive global development and commercialization rights to SSGJ-707, with the total potential deal value exceeding US$6 billion. The company is also entitled to tiered double-digi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/3sbio-announces-2025-annual-results-dual-engines-of-innovative-rd-and-global-collaboration-propel-revenue-past-rmb-10-billion-milestone-302729335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4592","BK1583","BK4007","LU1066053197.SGD","PFE","BRVO","ITP","LU0985481810.HKD","LU1894683264.USD","BK7095","LU0170899867.USD","SG9999003800.SGD","BK4218","IE00BLSP4452.SGD","BK4581","IE00B19Z3B42.SGD","BK1161","BK4585","ADA.AU","IE0002270589.USD","BK4588","IBD","SG9999013999.USD","BK4077","SG9999011175.SGD","BK4568","IE000M9KFDE8.USD","SG9999001176.USD","LU0321505868.SGD","BK4534","LU0225284248.USD","LU1894683348.USD","SAA","BK1593","01530","LU0321505439.SGD","SLE","IND.AU","LU0306806265.USD","BK4599","BK7016","LU0456855351.SGD","SG9999002232.USD","CLDT","BK4181","HK0000165453.HKD","LU0289739699.SGD","LU1883839398.USD","IE00B19Z3581.USD","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623132199","title":"3SBio (SEHK:1530) Valuation Check After Strong 2025 Sales And Earnings Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2623132199","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623132199?lang=en_us&edition=full_marsco","pubTime":"2026-03-31 03:06","pubTimestamp":1774897576,"startTime":"0","endTime":"0","summary":"3SBio (SEHK:1530) just released full year 2025 results, reporting sales of CNY 17,695.75 million and net income of CNY 8,482.16 million, drawing fresh attention to the stock’s recent move.\nSee our latest analysis for 3SBio.\nThe earnings release follows a board meeting earlier in March that highlighted these results and a potential final dividend. The strong full year figures appear to align with fresh interest in the stock, with a 7 day share price return of 13.25% and a 1 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/3sbio-sehk1530-valuation-check-after-strong-2025-sales-and-e","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/3sbio-sehk1530-valuation-check-after-strong-2025-sales-and-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK1593","BK1161","HK0000165453.HKD","BK1583","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194363500","title":"3SBIO Reports Fiscal Year Profit Attributable to Owners Soars 305.8% to RMB 8.482 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1194363500","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194363500?lang=en_us&edition=full_marsco","pubTime":"2026-03-30 22:32","pubTimestamp":1774881158,"startTime":"0","endTime":"0","summary":"3SBIO (01530) announced its full-year results for the period ending December 31, 2025. The Group's revenue increased by 94.3% to RMB 17.696 billion. Gross profit rose by 108.8% to RMB 16.347 billion,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","01530","HK0000165453.HKD","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149079082","title":"3SBio to Spin Off Mandi Inc.; Board Declares Conditional Special Dividend via Distribution in Specie","url":"https://stock-news.laohu8.com/highlight/detail?id=1149079082","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149079082?lang=en_us&edition=full_marsco","pubTime":"2026-03-30 21:44","pubTimestamp":1774878288,"startTime":"0","endTime":"0","summary":"3SBio Inc. (3SBio) announced plans to spin off its wholly owned subsidiary, Mandi Inc., for a separate listing on the Main Board of the Stock Exchange of Hong Kong. In tandem, the board declared a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190120580","title":"3SBio Declares HKD0.25 Final Dividend for FY-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1190120580","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190120580?lang=en_us&edition=full_marsco","pubTime":"2026-03-30 21:44","pubTimestamp":1774878273,"startTime":"0","endTime":"0","summary":"3SBio Inc. has announced a final ordinary dividend of HKD0.25 per share for the financial year ended 31 December 2025, according to a filing with the Hong Kong Stock Exchange dated 30 March 2026....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623458783","title":"3SBio proposes final dividend of HKD 0.25 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2623458783","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623458783?lang=en_us&edition=full_marsco","pubTime":"2026-03-30 21:36","pubTimestamp":1774877785,"startTime":"0","endTime":"0","summary":"3SBio proposed a final dividend for fiscal 2025 of HKD 0.25 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 3SBio Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL2Zf5Lf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","HK0000165453.HKD","BK1583","BK1161","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623345381","title":"3SBio FY25 net profit jumps to RMB 8.5 billion; revenue rises 94.3% to RMB 18 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2623345381","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623345381?lang=en_us&edition=full_marsco","pubTime":"2026-03-30 21:36","pubTimestamp":1774877770,"startTime":"0","endTime":"0","summary":"3SBio posted net profit attributable to owners of parent up 305.8% to RMB 8.5 billion for year ended Dec. 31, 2025.Board proposed final dividend of HKD 0.25 per share.Pipeline and corporate updates included out-licensing PD-1/VEGF bispecific antibody 707 to Pfizer with USD 1.25 billion upfront payment; company also advanced Mandi spin-off plan with HKEx application submitted.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 3SBio Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL9gwHKK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0170899867.USD","SGXZ57979304.SGD","BK4581","LU0225284248.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","IE00BLSP4452.SGD","LU0306806265.USD","SG9999001176.SGD","01530","BK1583","LU1894683348.USD","LU0122379950.USD","SG9999002224.SGD","BK4592","LU0985481810.HKD","BK4550","BK4007","BK4585","LU0321505868.SGD","BK1161","LU0456855351.SGD","BK4568","LU0868494617.USD","BK4533","BK4534","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU0306807586.USD","LU1066053197.SGD","LU0058720904.USD","SG9999002232.USD","LU0225771236.USD","LU0321505439.SGD","SG9999011175.SGD","SG9999003800.SGD","SG9999013999.USD","IE00BBT3K403.USD","IE00BLSP4239.USD","BK1593","LU1066051498.USD","HK0000165453.HKD","LU0234572021.USD","SG9999001176.USD","IE0002270589.USD","BK4588","BK4599","LU1057294990.SGD","LU1023059063.AUD","LU1883839398.USD","LU1894683264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620230200","title":"Alphamab Oncology Names Former 3SBio Executive as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2620230200","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620230200?lang=en_us&edition=full_marsco","pubTime":"2026-03-18 19:32","pubTimestamp":1773833554,"startTime":"0","endTime":"0","summary":"Alphamab Oncology (HKG:9966) named Wang Fei as its chief financial officer effective March 16, according to a Wednesday Hong Kong bourse filing.Wang was the CFO of 3SBio (HKG:1530) from April 2020 to April 2023.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01530","BK1161","BK1593","BK1583","HK0000165453.HKD","BK1574","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165555890","title":"CMB International Foresees Accelerated Fundamental Improvement in China's Healthcare Sector, Recommends Buying Innovent Bio, 3SBIO, and Others","url":"https://stock-news.laohu8.com/highlight/detail?id=1165555890","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165555890?lang=en_us&edition=full_marsco","pubTime":"2026-03-17 15:20","pubTimestamp":1773732029,"startTime":"0","endTime":"0","summary":"According to a research report from CMB International, the MSCI China Healthcare Index has risen 0.6% since the beginning of 2026, outperforming the MSCI China Index by 3.5 percentage points. The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2097828805.USD","LU2488822045.USD","LU0455707207.USD","LU2097828474.EUR","HK0000165453.HKD","BK1589","01167","01530","02268","BK1219","LU2328871848.SGD","LU2097828714.EUR","SG9999014674.SGD","LU2097828557.USD","01801","BK1141","LU2242644610.SGD","BK1583","LU1969619763.USD","LU0502904849.HKD","BK1574","BK1593","LU2097828631.EUR","159891","02273"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115207358","title":"Biopharma Stocks Rally as Sector Gains Strategic \"Emerging Pillar\" Status","url":"https://stock-news.laohu8.com/highlight/detail?id=1115207358","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115207358?lang=en_us&edition=full_marsco","pubTime":"2026-03-06 10:14","pubTimestamp":1772763264,"startTime":"0","endTime":"0","summary":"Innovative drug stocks strengthened during the morning session. At the time of writing, HUTCHMED (00013) rose 9.02% to HK$22.96; 3SBIO (01530) increased 8.41% to HK$21.4; HENGRUI PHARMA (01276)...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2543165471.USD","BK4585","159992","01530","LU0455707207.USD","LU0359201612.USD","LU1969619763.USD","BK4588","02162","LU2097828474.EUR","161726","LU2097828714.EUR","00013","BK1583","BK1593","01801","LU2328871848.SGD","LU0502904849.HKD","LABU","VT","399441","LU0359202008.SGD","LU2097828631.EUR","LU2097828557.USD","LU2488822045.USD","BK1588","BK1191","LU1023057109.AUD","06978","LU0359201885.HKD","BK1589","LU2242644610.SGD","VXUS","BK1574","01276","LU2097828805.USD","HK0000165453.HKD","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122337657","title":"3SBio Inc. (01530) Publishes February 2026 Monthly Securities Return","url":"https://stock-news.laohu8.com/highlight/detail?id=1122337657","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122337657?lang=en_us&edition=full_marsco","pubTime":"2026-03-03 16:43","pubTimestamp":1772527409,"startTime":"0","endTime":"0","summary":"3SBio Inc. (the “Company”) released its monthly securities return for the period ended 28 February 2026. The Company’s authorized share capital remains at 50.00 billion ordinary shares, each with a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148570608","title":"UBS Forecasts 10% Revenue Growth for Healthcare Sector This Year, Names 3SBIO as Top Pick","url":"https://stock-news.laohu8.com/highlight/detail?id=1148570608","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148570608?lang=en_us&edition=full_marsco","pubTime":"2026-03-02 14:07","pubTimestamp":1772431669,"startTime":"0","endTime":"0","summary":"UBS has released a research report projecting that the median revenue growth for rated healthcare companies will reach 16% in 2025 and 10% in 2026, based on the latest industry sales data and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU1023057109.AUD","LU1226288253.USD","LU1993786604.SGD","LU1226287529.USD","IE0008368742.USD","XLV","IE00B031HY20.USD","LU1226288170.HKD","LU0314109678.HKD","BK4585","LU1813983027.USD","SG9999004220.SGD","LU0315179316.USD","LU1807302812.USD","LU1960683339.HKD","IE00BZ08YR35.GBP","BK1589","BK1593","BK1521","LU1152091168.USD","LU1226287875.USD","LU1008478684.HKD","LU1328277881.USD","01093","BK1515","XBI","03692","LU0880133367.SGD","LU0359202008.SGD","IE00B543WZ88.USD","LU2039709279.SGD","159760","LABU","LU0067412154.USD","LU1152091754.HKD","BK1161","LU0359201612.USD","LU0359201885.HKD","LU0140636845.USD","IE00BZ08YS42.EUR","LU1226287792.SGD","LU0326950275.SGD","LU1951186391.HKD","BK4581","BK1191","LU0501845795.SGD","01530","BK4588","IE00B5MMRT66.SGD","LU0072913022.USD","LU2543165471.USD","HK0000165453.HKD","01276","IE0008369823.USD","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":-0.1017},{"period":"1month","weight":0.043},{"period":"3month","weight":-0.1757},{"period":"6month","weight":-0.1886},{"period":"1year","weight":1.0375},{"period":"ytd","weight":-0.0571}],"compareEarnings":[{"period":"1week","weight":0.0253},{"period":"1month","weight":-0.008},{"period":"3month","weight":-0.0183},{"period":"6month","weight":-0.0205},{"period":"1year","weight":0.2708},{"period":"ytd","weight":0.0048}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"3SBio Inc is an investment holding company principally engaged in the development, production, marketing and sale of biopharmaceutical products. The Company's main products include biopharmaceuticals such as TPIAO, EPIAO, Yisaipu, and Cipterbin, as well as small moleculessuch as Mandi and Remitch. The Company is also engaged in the contract development and manufacturing operations (CDMO) business that provides customers with research, development and production of a variety of biopharmaceuticals and therapeutic technology platform services. The Company's products are mainly used for chemotherapy-induced thrombocytopenia (CIT), anemia caused by chronic kidney disease (CKD), treatment of chemotherapy-induced anemia (CIA), ankylosing spondylitis (AS) and psoriasis. The Company mainly operates its businesses in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.00666},{"month":2,"riseRate":0.454545,"avgChangeRate":0.00178},{"month":3,"riseRate":0.818182,"avgChangeRate":0.113214},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.012446},{"month":5,"riseRate":0.7,"avgChangeRate":0.109101},{"month":6,"riseRate":0.8,"avgChangeRate":0.036581},{"month":7,"riseRate":0.090909,"avgChangeRate":-0.038254},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.014022},{"month":9,"riseRate":0.636364,"avgChangeRate":0.027455},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.018307},{"month":11,"riseRate":0.727273,"avgChangeRate":0.059913},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.045323}],"exchange":"SEHK","name":"3SBIO","nameEN":"3SBIO"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"3SBIO(01530),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest 3SBIO(01530) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"3SBIO,01530,3SBIO股票,3SBIO股票老虎,3SBIO股票老虎国际,3SBIO行情,3SBIO股票行情,3SBIO股价,3SBIO股市,3SBIO股票价格,3SBIO股票交易,3SBIO股票购买,3SBIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"3SBIO(01530),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest 3SBIO(01530) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}